Guggenheim Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Announces Target Price $90
H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $80
A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $44 to $78
Celldex Therapeutics (NASDAQ:CLDX) Pulls Back 6.1% This Week, but Still Delivers Shareholders Fantastic 57% CAGR Over 5 Years
Celldex: Barzolvolimab has reached the endpoint in chronic urticaria research.
Biopharmaceutical company Celldex Therapeutics announced that in the study of chronic inducible urticaria, Barzolvolimab achieved all primary and secondary endpoints with high statistical significance. Barzolvolimab (CDX 0159) is a humanized anti-KIT IgG1 monoclonal antibody. Barzolvolimab is specifically and effectively inhibiting the activation of KIT. Barzolvolimab can reduce skin mast cells and disease activity in chronic inducible urticaria. According to a report
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints With High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
